BioAge Labs, Inc., the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from Morgan Stanley maintained a Sell rating on the stock and has a $5.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Michael Ulz has given his Sell rating due to a combination of factors related to BioAge Labs, Inc.’s current financial and operational status. Despite the company’s progress in its clinical pipeline, including the upcoming Phase 1 study for BGE-102 and expansion of the APJ agonist pipeline, there are concerns about the timing and outcomes of these developments. The anticipated initial data from the BGE-102 study is not expected until the end of 2025, with further data following in mid-2026, which introduces a degree of uncertainty and delay in potential revenue generation.
Additionally, while BioAge has a significant cash reserve expected to support operations through 2029, the company’s current market capitalization and share price suggest that investors may have reservations about its near-term growth prospects. The ongoing collaborations and patent filings, although promising, have yet to translate into tangible financial returns, contributing to the cautious outlook reflected in the Sell rating.
BIOA’s price has also changed slightly for the past six months – from $4.370 to $4.320, which is a -1.14% drop .